| Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study DG Rothwell, M Ayub, N Cook, F Thistlethwaite, L Carter, E Dean, N Smith, ... Nature medicine 25 (5), 738-743, 2019 | 237 | 2019 |
| A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or … E Van Cutsem, YJ Bang, W Mansoor, RD Petty, Y Chao, D Cunningham, ... Annals of Oncology 28 (6), 1316-1324, 2017 | 164 | 2017 |
| A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung CancersPhase Ib Study of AZD4547 in FGFR-Amplified SQCLC PK Paik, R Shen, MF Berger, D Ferry, JC Soria, A Mathewson, C Rooney, ... Clinical cancer research 23 (18), 5366-5373, 2017 | 133 | 2017 |
| An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer T Powles, D Carroll, S Chowdhury, G Gravis, F Joly, J Carles, A Fléchon, ... Nature Medicine 27 (5), 793-801, 2021 | 67 | 2021 |
| A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor … YJ Bang, E Van Cutsem, W Mansoor, RD Petty, Y Chao, D Cunningham, ... Journal of Clinical Oncology 33 (15_suppl), 4014-4014, 2015 | 67 | 2015 |
| Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study H Saka, C Kitagawa, Y Kogure, Y Takahashi, K Fujikawa, T Sagawa, ... Investigational new drugs 35, 451-462, 2017 | 57 | 2017 |
| Complexity of FGFR signalling in metastatic urothelial cancer A Rodriguez-Vida, M Saggese, S Hughes, S Rudman, S Chowdhury, ... Journal of Hematology & Oncology 8, 1-8, 2015 | 56 | 2015 |
| A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. PK Paik, R Shen, D Ferry, JC Soria, A Mathewson, E Kilgour, D Landers, ... Journal of clinical oncology, 2014 | 51 | 2014 |
| An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies T Powles, A Balar, G Gravis, R Jones, A Ravaud, J Florence, P Grivas, ... Annals of Oncology 30, v356-v357, 2019 | 32 | 2019 |
| Assessing the communication gap between AI models and healthcare professionals: explainability, utility and trust in AI-driven clinical decision-making O Wysocki, JK Davies, M Vigo, AC Armstrong, D Landers, R Lee, A Freitas Artificial Intelligence 316, 103839, 2023 | 24 | 2023 |
| Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer RC Coombes, PD Badman, JP Lozano-Kuehne, X Liu, IR Macpherson, ... Nature Communications 13 (1), 3246, 2022 | 24 | 2022 |
| A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. HT Arkenau, M Saggese, A Hollebecque, A Mathewson, CR Lemech, ... Journal of Clinical Oncology 32 (15_suppl), 2620-2620, 2014 | 23 | 2014 |
| Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast … SRD Johnston, M Basik, R Hegg, W Lausoontornsiri, L Grzeda, ... Journal of Clinical Oncology 31 (15_suppl), 531-531, 2013 | 20 | 2013 |
| RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients … M Seckl, PD Badman, X Liu, IR MacPherson, IH Zubairi, RD Baird, ... Journal of Clinical Oncology 35 (15_suppl), 1059-1059, 2017 | 17 | 2017 |
| Wave comparisons of clinical characteristics and outcomes of COVID-19 admissions-Exploring the impact of treatment and strain dynamics A Freeman, A Watson, P O'Regan, O Wysocki, H Burke, A Freitas, ... Journal of Clinical Virology 146, 105031, 2022 | 16 | 2022 |
| Research evaluation alongside clinical treatment in COVID-19 (REACT COVID-19): an observational and biobanking study H Burke, A Freeman, A Dushianthan, M Celinski, J Batchelor, H Phan, ... BMJ open 11 (1), e043012, 2021 | 12 | 2021 |
| A systematic review of biologically-informed deep learning models for cancer: fundamental trends for encoding and interpreting oncology data M Wysocka, O Wysocki, M Zufferey, D Landers, A Freitas | 11 | 2022 |
| Establishment of CORONET, COVID-19 risk in oncology evaluation tool, to identify patients with cancer at low versus high risk of severe complications of COVID-19 disease on … RJ Lee, O Wysocki, C Zhou, R Shotton, A Tivey, L Lever, J Woodcock, ... JCO clinical cancer informatics 6, e2100177, 2022 | 11 | 2022 |
| BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer. T Powles, E Kilgour, R Mather, A Galer, HT Arkenau, A Farnsworth, ... Journal of Clinical Oncology 34 (15_suppl), TPS4577-TPS4577, 2016 | 10 | 2016 |
| Transformers and the representation of biomedical background knowledge O Wysocki, Z Zhou, P O’Regan, D Ferreira, M Wysocka, D Landers, ... Computational Linguistics, 1-43, 2022 | 9 | 2022 |
